Aspirin shows inferior efficacy in curbing blood clot risk in myeloma

09/11/2013 | MyelomaBeacon.com

A French study in the journal Thrombosis and Haemostasis found that aspirin was inferior to vitamin K antagonists and low-molecular weight heparin in preventing blood clots in myeloma patients taking Revlimid or thalidomide. The results suggest that clinicians prescribe low-molecular weight heparin or vitamin K antagonists to high-risk patients and that treatment should be continued as needed to address clotting risk, researchers said.

View Full Article in:

MyelomaBeacon.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID